Friday 6 November 2026 Export COGT’s income statement to Excel — free account

Cogent Biosciences, Inc.

COGT Healthcare Biotechnology

EPS: +1.89%
Free cash flow: −42.0%

Quarter to June 2026, against a year earlier

31.60 2.02 +6.83%

Follow COGT

Alert me

Market cap: $5.1B
P/E: 0.0×
Fwd P/E: −5.2×
Dividend yield: —
F-score: 3/9
Altman Z: 3.55
Beneish M: n/a
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Sold, $m 383.89

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	4	1	—	1	—	—	—	—	1	—	—	—

Insider Ownership 8.87%

Capital & Financial Ratios $m

Size

Market Cap 5,130.00

Revenue ttm 23.16

Net income ttm (377.18)

Free cash flow ttm (309.24)

Net debt Q (568.84)

Valuation

P/E 0.00

Forward P/E (5.21)

Price / sales 233.33

Forward P/S Powerpack

Price / FCF 0.00

Price / book 11.56

Financial health

Current ratio Q 13.57

Debt / equity Q 0.42

Interest coverage Q (84.34)

Growth

Revenue growth Q −69.41%

Operating income growth Q −35.80%

EPS, this year −3.86%

EPS, next year A +49.48%

Revenue, next year A +0.62%

EPS, past 5 yrs —

EPS, next 5 yrs A +36.85%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 94.23%

10-year low 10-year high

P/B against its own 10 years 91.75%

10-year low 10-year high

EV/Sales against its own 10 years 93.01%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	266	287	901	792
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	271	296	910	805

	2023	2024	2025	Q'26
Payables	11	12	10	7
ST’ Debt	—	—	—	—
Other	—	—	—	—
	38	56	64	59

Compound Annual Growth %

	10y	5y	3y
Sales	—	21.39%	(1.99%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	22.08%	35.51%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.55 Actual −0.52

−0.58 −0.56 −0.53 −0.51 −0.49

Q3 FY25 Beat +0.04

Q4 FY25 Miss −0.04

Q1 FY26 Met 0.00

Q2 FY26 Beat +0.03

Q3 FY26 — Nov 5

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q3 FY25	−0.54	−0.50	Beat by 0.04
Q4 FY25	−0.51	−0.55	Miss by 0.04
Q1 FY26	−0.53	−0.53	Met by 0.00
Q2 FY26	−0.55	−0.52	Beat by 0.03
Q3 FY26	−0.57	—	Reports 5 November 2026

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.53)	(0.52)	—	—	—
’25	(0.52)	(0.53)	(0.50)	(0.61)	(2.16)
’24	(0.62)	(0.59)	(0.64)	(0.61)	(1.94)
’23	(0.54)	(0.59)	(0.64)	(0.63)	(2.42)
’22	(0.68)	(0.71)	(0.50)	(0.56)	(2.39)
’21	(0.34)	(0.43)	(0.48)	(0.61)	(1.87)
’20	(0.80)	(0.96)	(5.07)	(6.06)	(16.17)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’20	7	1	0	—	8
’19	3	3	1	15	22
’18	2	2	2	4	10
’17	2	2	2	2	8

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(87)	(77)	—	—	—
’25	(67)	(55)	(64)	(79)	(264)
’24	(53)	(43)	(52)	(61)	(208)
’23	(40)	(32)	(38)	(44)	(154)
’22	(28)	(26)	(34)	(29)	(119)
’21	(11)	(13)	(14)	(21)	(59)
’20	(8)	(8)	(10)	(9)	(36)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(87)	(78)	—	—	—
’25	(67)	(55)	(64)	(80)	(266)
’24	(53)	(43)	(52)	(61)	(208)
’23	(41)	(33)	(38)	(44)	(156)
’22	(29)	(28)	(38)	(31)	(126)
’21	(11)	(13)	(15)	(21)	(60)
’20	(8)	(8)	(2)	(9)	(27)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Jun ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	6	8	10	22	8	—	—	—	—	—	23		+5.5%	6	284	761	+1,027.5%
	Gross margin, %	100.00	100.00	100.00	100.00	100.00	0.00	0.00	—	—	—	0.00		(100.0) pt	Powerpack Cogent Biosciences, Inc.’s next three years, line by line Analysts expect revenue to grow 1,027.5% a year to 2028 — faster than the 5.5% of the last 4 years. See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(18)	(25)	(35)	(32)	(75)	(72)	(140)	(192)	(256)	(329)	(377)		+38.0%
	EBT margin, %	(285.19)	(304.93)	(354.76)	(141.49)	(950.43)	0.00	0.00	0.00	0.00	0.00	0.00		+285.2 pt
	Net income	(18)	(25)	(35)	(32)	(75)	(72)	(140)	(192)	(256)	(329)	(377)		+38.0%
Per share, $
Per share, $	Revenue	2.49	3.28	1.56	2.95	0.71	0.00	0.00	0.00	0.00	0.00	0.00		n/m
	Earnings	(7.11)	(10.00)	(5.56)	(4.16)	(16.17)	(1.87)	(2.39)	(2.42)	(1.94)	(2.16)	(2.16)		(12.4%)
	Cash flow	(7.32)	(10.14)	(5.22)	(5.45)	(3.24)	(1.52)	(2.02)	(1.93)	(2.00)	(2.05)	(1.80)		(13.2%)
	Capex	(1.30)	(0.36)	(0.09)	0.02	0.76	(0.04)	(0.12)	(0.04)	(0.01)	(0.01)	(0.01)		(40.5%)
	Free cash flow	(8.62)	(10.50)	(5.31)	(5.43)	(2.48)	(1.56)	(2.14)	(1.96)	(2.01)	(2.06)	(1.81)		(14.7%)
	Book value	(9.69)	(19.17)	9.68	4.17	21.18	5.53	4.35	3.24	2.47	4.94	3.11		n/m
	Shares, m	3	3	6	8	11	39	59	80	104	129	150		+54.6%
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—	0.00		0.0
	P/S	13.52	13.52	11.25	0.98	5.37	—	—	—	—	—	233.33		8.9
	P/B	0.00	0.00	1.82	0.69	1.01	—	—	—	—	—	11.56		0.7
	EV/Sales	8.62	8.62	3.18	(0.49)	(4.95)	—	—	—	—	—	208.77		3.0
	EV/FCF	(2.70)	(2.70)	(0.94)	0.27	4.21	—	—	—	—	—	(15.63)		(0.4)
Cash, $m
Cash, $m	Operating cash flow	(19)	(26)	(32)	(42)	(36)	(59)	(119)	(154)	(208)	(264)	(308)		+34.3%
	Capex	(3)	(1)	(1)	0	8	(2)	(7)	(3)	(1)	(2)	(2)		(8.0%)
	Free cash flow	(22)	(27)	(33)	(41)	(27)	(60)	(126)	(156)	(208)	(266)	(309)		+31.9%
Balance, $m
Balance, $m	Working capital	61	31	56	27	232	206	238	233	241	846	746		+33.9%
	Net debt	(69)	(41)	(79)	(33)	(239)	(219)	(242)	(266)	(287)	(678)	(569)		+29.0%
	Shareholders’ equity	(25)	(49)	60	32	235	214	256	258	256	636	532		n/m
Returns, %
Returns, %	ROA	(48.15)	(41.00)	(51.17)	(47.04)	(119.34)	(29.93)	(52.63)	(62.65)	(79.79)	(51.99)	(68.00)		(3.8) pt
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	(688.01)	0.00	0.00	0.00	0.00		0.0 pt
	ROE	49.46	69.50	(606.74)	(69.21)	(230.42)	(57.23)	(88.01)	(99.26)	(148.99)	(94.98)	(146.55)		(144.4) pt
People
People	Employees	—	53	56	72	15	77	138	164	205	258	—		+21.9%
	Revenue/emp, $m	0.00	0.16	0.17	0.31	0.52	0.00	0.00	0.00	0.00	0.00	—		n/m

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2020 · latest quarter Sep 2020

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
IMVT Immunovant, Inc.	$5.9B	— (loss-making)	—	—	n/m	−5.96% (below 0%: shrinking)	0.00%	0.00%	Compare
CGON CG Oncology, Inc.	$5.7B	— (loss-making)	— (loss-making)	+2,125.00% (above 0%: growing)	n/m	−67.60% (below 0%: shrinking)	(239.24%)	(7,467.68%)	Compare
SRRK Scholar Rock Holding Corporation	$5.5B	— (loss-making)	— (loss-making)	+605.03% (above 0%: growing)	n/m	+8.88% (above 0%: growing)	0.00%	0.00%	Compare
PTCT PTC Therapeutics, Inc.	$5.5B	— (loss-making)	42.2×	+69.57% (above 0%: growing)	n/m	+90.28% (above 0%: growing)	93.39%	7.02%	Compare
MANE Veradermics Incorporated	$5.4B	— (loss-making)	—	—	n/m	−8.81% (below 0%: shrinking)	—	0.00%	Compare
COGT Cogent Biosciences, Inc.	$5.1B	— (loss-making)	— (loss-making)	−69.41% (below 0%: shrinking)	n/m	−42.01% (below 0%: shrinking)	0.00%	0.00%
CRSP CRISPR Therapeutics AG	$4.7B	— (loss-making)	— (loss-making)	+1,325.08% (above 0%: growing)	n/m	−6.36% (below 0%: shrinking)	100.00%	(1,026.48%)	Compare
TVTX Travere Therapeutics, Inc.	$4.7B	— (loss-making)	— (loss-making)	+36.22% (above 0%: growing)	n/m	+6,379.75% (above 0%: growing)	98.72%	(30.33%)	Compare
ERAS Erasca, Inc.	$4.6B	— (loss-making)	—	—	n/m	−4.67% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$5.4B	—	—	+605.03%	—	−5.31%	0.00%	0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 23 April 2026

Chief executive’s pay

Year	Total pay	Actually paid	$100 invested
2025	27.76m	116.77m	413.99
2024	4.92m	11.88m	90.91
2023	7.90m	(201.50k)	68.53
2022	4.39m	9.82m	134.73

Ownership

Directors and executive officers, together 6.59%

Entities affiliated with FMR LLC 9.70%

Entities affiliated with Fairmount Funds Management LLC 8.50%

The Vanguard Group 6.74%

Entities affiliated with BlackRock, Inc. 6.66%

Entities affiliated with Deerfield Mgmt, L.P. 5.30%

Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Cogent Biosciences, Inc. (COGT) Latest News

5 Nov

Impact 4 · 4:01 PM · GlobeNewswire

Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2026 Financial Results

27 Oct

Impact 3 · 4:01 PM · GlobeNewswire

Cogent Biosciences to Participate in the Guggenheim Healthcare Innovation Conference

20 Oct

Impact 4 · 12:32 PM · Insider Monkey

Cogent Biosciences (COGT) Nears Three FDA Decisions. What Is Its Pipeline Worth?

25 Sep

Impact 4 · 6:10 AM · Simply Wall St.

Cogent Biosciences (COGT) Stock Trades At A Premium As FDA Accepts NDA

24 Sep

Impact 3 · 2:12 PM · Simply Wall St.

Cogent Biosciences (COGT) Looks Fully Valued Following FDA NDA Acceptance

Impact 3 · 8:11 AM

Will FDA’s Streamlined Bezuclastinib Review in ASM Change Cogent Biosciences’ (COGT) Narrative?

15 Sep

Impact 4 · 8:00 AM

Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

15 Jul

Impact 4 · 10:01 AM

Cogent Bioscience (COGT) Files New Drug Application For Bezuclastinib

30 Jun

Impact 4 · 8:00 AM

Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)

22 Jun

Impact 4 · 10:14 AM · Insider Monkey

Is Cogent Biosciences (COGT) ’s New Cancer Drug 100 Times More Precise Than What’s Already on the Market?

12 Jun

Impact 4 · 8:58 AM

Cogent Biosciences' Potential Rare Blood Disease Treatment Meets Endpoints in Clinical Trial

Impact 4 · 8:00 AM

Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress

Impact 3 · 8:01 AM

Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress

9 Jun

Impact 4 · 10:13 PM · Simply Wall St.

How Investors May Respond To Cogent Biosciences (COGT) Priority Review For Bezuclastinib GIST Regimen

30 May

Impact 4 · 8:00 AM · GlobeNewswire

Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

28 May

Impact 4 · 8:00 AM · GlobeNewswire

Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST

17 May

Impact 4 · 2:52 PM · The Motley Fool

This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million

Impact 4 · 2:42 PM · The Motley Fool

This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million

12 May

Impact 3 · 9:30 AM · GlobeNewswire

Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress

7 May

Impact 4 · 2:26 AM · Simply Wall St.

Cogent Biosciences (COGT) Valuation After Wider Q1 Loss And Bezuclastinib Regulatory Progress

5 May

Impact 3 · 8:00 AM · GlobeNewswire

Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results

21 Apr

Impact 5 · 8:00 AM

Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

11 Apr

Impact 4 · 11:10 PM · Simply Wall St.

Does Bezuclastinib’s Real-Time FDA Review and NDA Filing Change The Bull Case For Cogent Biosciences (COGT)?

1 Apr

Impact 5 · 8:00 AM · GlobeNewswire

Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST)

23 Mar

Impact 4 · 6:08 PM

A Look At Cogent Biosciences (COGT) Valuation After FDA NDA Acceptance And Shifting Institutional Positions

21 Mar

Impact 4 · 7:33 PM · The Motley Fool

This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch

Impact 3 · 6:18 PM · The Motley Fool

Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish

20 Mar

Impact 4 · 12:27 PM · The Motley Fool

Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026

17 Mar

Impact 4 · 1:08 PM · Simply Wall St.

What Cogent Biosciences (COGT)'s FDA Acceptance of Bezuclastinib NDA Means For Shareholders

Impact 4 · 11:38 AM · Zacks

COGT Rise as FDA Accepts Bezuclastinib NDA in Non-Advanced SM

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Cogent Biosciences, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 23 April 2026

Chief executive’s pay

Ownership

Cogent Biosciences, Inc. (COGT) Latest News

5 Nov

27 Oct

20 Oct

25 Sep

24 Sep

15 Sep

15 Jul

30 Jun

22 Jun

12 Jun

9 Jun

30 May

28 May

17 May

12 May

7 May

5 May

21 Apr

11 Apr

1 Apr

23 Mar

21 Mar

20 Mar

17 Mar

COGT metrics, ten years each

Stockrow Weekly